NASDAQ:ARQT

Arcutis Biotherapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy ARQT

*Your capital is at risk

$21.35

+0.560 (+2.69%)

At Close: Jun 03, 2026

Arcutis Biotherapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -66.86. In total, the insiders bought 1.14M and sold 561.57K ARQT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-66.86
● Buy	1.14M shares
● Sell	561.57K shares
33% Buy Activity Weak Negative Correlation
Buy Signal Low Confidence Feb 27, 2026 Analysis Breakdown: Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -66.86. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 02, 2026 Sell	Common Stock S-Sale	Vairavan Latha SVP Chief Financial Officer	C-Suite Officer	81 Value: $2K
Feb 27, 2026 Buy	Stock Option (right to buy) A-Award	Burnett Patrick See Remarks	Officer	77 000 Value: $2.08M
Feb 27, 2026 Buy	Common Stock A-Award	Burnett Patrick See Remarks	Officer	30 000 Value: $809.1K
Feb 27, 2026 Buy	Common Stock A-Award	Vairavan Latha SVP Chief Financial Officer	C-Suite Officer	27 000 Value: $728.2K
Feb 27, 2026 Buy	Stock Option (right to buy) A-Award	Matsuda Masaru See Remarks	Officer	97 000 Value: $2.62M
Feb 27, 2026 Buy	Common Stock A-Award	Matsuda Masaru See Remarks	Officer	37 000 Value: $997.9K
Feb 27, 2026 Buy	Stock Option (right to buy) A-Award	Watanabe Todd See Remarks	Officer	266 000 Value: $7.17M
Feb 27, 2026 Buy	Common Stock A-Award	Watanabe Todd See Remarks	Officer	102 000 Value: $2.75M
Feb 27, 2026 Buy	Stock Option (right to buy) A-Award	Edwards Larry Todd See Remarks	Officer	77 000 Value: $2.08M
Feb 27, 2026 Buy	Common Stock A-Award	Edwards Larry Todd See Remarks	Officer	30 000 Value: $809.1K
Feb 27, 2026 Sell	Common Stock S-Sale	Matsuda Masaru See Remarks	Officer	3 325 Value: $92.9K
Feb 27, 2026 Buy	Stock Option (right to buy) A-Award	Vairavan Latha SVP Chief Financial Officer	C-Suite Officer	70 000 Value: $1.89M
Feb 04, 2026 Sell	Common Stock S-Sale	Burnett Patrick See Remarks	Officer	9 794 Value: $252.7K
Feb 02, 2026 Sell	Common Stock S-Sale	Matsuda Masaru See Remarks	Officer	7 983 Value: $203.6K
Feb 02, 2026 Sell	Common Stock S-Sale	Matsuda Masaru See Remarks	Officer	8 562 Value: $213.8K
Feb 02, 2026 Sell	Common Stock S-Sale	Matsuda Masaru See Remarks	Officer	19 379 Value: $489.1K
Feb 02, 2026 Sell	Common Stock S-Sale	Matsuda Masaru See Remarks	Officer	4 714 Value: $120.8K
Feb 02, 2026 Sell	Common Stock S-Sale	Burnett Patrick See Remarks	Officer	3 675 Value: $93.7K
Feb 02, 2026 Sell	Common Stock S-Sale	Watanabe Todd See Remarks	Officer	19 833 Value: $505.7K
Feb 02, 2026 Sell	Common Stock S-Sale	Vairavan Latha SVP Chief Financial Officer	C-Suite Officer	1 320 Value: $33.7K
Feb 02, 2026 Sell	Common Stock S-Sale	Welgus Howard G. Director	Director	10 000 Value: $250.5K
Feb 02, 2026 Sell	Common Stock S-Sale	Edwards Larry Todd See Remarks	Officer	2 052 Value: $52.3K
Jan 05, 2026 Sell	Common Stock S-Sale	Burnett Patrick See Remarks	Officer	2 490 Value: $72.2K
Jan 02, 2026 Sell	Common Stock S-Sale	Welgus Howard G. Director	Director	10 000 Value: $289.6K
Dec 31, 2025 Sell	Common Stock S-Sale	Burnett Patrick See Remarks	Officer	1 156 Value: $34.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ARCUTIS BIOTHERAPEUTICS INC

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp ...

Read Full Profile Here